Want to see ELV full AI Analyst Report?
Earnings Data
Report Date
Jul 15, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
6.21Last Year’s EPS
8.84Same Quarter Last Year
Moderate Buy
Based on 19 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized strong execution and tangible operational improvements that drove a Q1 EPS beat, an upgraded full-year EPS guide, share repurchases and growing demand for integrated clinical and pharmacy offerings. Management also highlighted meaningful AI investments and measurable clinical results from Carelon/CareBridge (20% readmission reduction, >10% post-acute savings). Offsetting these positives are a material $935 million accrual related to a CMS historical risk-adjustment matter, a $129 million optimization charge, ongoing elevated Medicaid cost trends and some margin pressure and investment-driven cadence at Carelon. On balance the positives (guidance raise, underlying business beats, membership growth, cash generation and scalable AI/Carelon proof points) outweigh the negatives (one-time accrual, Medicaid pressure, Carelon margin timing), supporting a constructive outlook with manageable risks.Company Guidance
Adjusted EPS Beat and Upgraded Full-Year Guidance
Reported Q1 adjusted diluted EPS of $12.58, which exceeded expectations. Raised full-year 2026 adjusted diluted EPS guidance to at least $26.75. Management notes the revised 2026 baseline excluding a nonrecurring ~$1.00 investment valuation item is $25.75, which underpins their plan to return to at least 12% adjusted EPS growth in 2027.
Membership and Revenue Growth
Ended March with 45.4 million members, up nearly 200,000 from year-end. Operating revenue totaled $49.5 billion, up 1.5% year-over-year.
Improved Expense Metrics and Operating Cash Flow
Consolidated benefit expense ratio was 86.8%. Adjusted operating expense ratio improved 20 basis points year-over-year to 10.5%. Operating cash flow was $4.3 billion in Q1 with a full-year target of at least $5.5 billion.
Capital Deployment and Share Repurchases
Repurchased 3.7 million shares for $1.1 billion in the quarter at an average price just over $300 per share. Company remains on track for at least $2.3 billion of share repurchases in 2026.
Carelon and CareBridge Clinical Impact
Carelon's integrated programs (CareBridge + Care at Home) reported a 20% reduction in hospital readmissions and more than 10% savings on post-acute care, supporting demand for risk-based solutions and whole-person care offerings.
Medicare and Commercial Momentum
Medicare Advantage performance improved and company remains on track to achieve an operating margin of at least 2% in 2026. Commercial selling momentum strong with record-level pipeline for 2027 sales and demonstrated employer wins for integrated medical-pharmacy solutions.
AI and Digital Investments Showing Early Traction
Investing more than $1 billion in digital and AI-enabled capabilities. Early proof points: AI-enabled virtual assistant used by ~22 million commercial members; personalized provider-matching tool connected with >20% of members; prior-authorization workflow reductions cited (denials reduced by ~70% in use cases). Over 60,000 associates have access to AI productivity tools.
Positive Operating Cash and Prior Year Development
Q1 prior-year development was approximately $250 million (non-material P&L impact in context). Management reiterated full-year operating cash flow target inclusive of potential cash payments related to CMS matter.
ELV Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ELV Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 22, 2026 | $326.78 | $326.87 | +0.03% |
Jan 28, 2026 | $319.64 | $338.38 | +5.86% |
Oct 21, 2025 | $348.68 | $344.42 | -1.22% |
Jul 17, 2025 | $337.46 | $296.23 | -12.22% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Elevance Health, Inc. (ELV) report earnings?
Elevance Health, Inc. (ELV) is schdueled to report earning on Jul 15, 2026, Before Open (Confirmed).
What is Elevance Health, Inc. (ELV) earnings time?
Elevance Health, Inc. (ELV) earnings time is at Jul 15, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ELV EPS forecast?
ELV EPS forecast for the fiscal quarter 2026 (Q2) is 6.21.
